Results 41 to 50 of about 8,764,171 (325)

AZD7648 is a potent and selective DNA-PK inhibitor that enhances radiation, chemotherapy and olaparib activity

Nature Communications, 2019
DNA-dependent protein kinase (DNA-PK) plays a major role in the DNA damage response upon double-strand break formation. Here, the authors show that the DNA-PK inhibitor AZD7648, enhances the activity of radiotherapy, chemotherapy and the PARP inhibitor ...
Jacqueline H. L. Fok, Antonio Ramos-Montoya, Mercedes Vazquez-Chantada, Paul W. G. Wijnhoven, Valeria Follia, Neil James, Paul M. Farrington, Ankur Karmokar, Sophie E. Willis, Jonathan Cairns, Jenni Nikkilä, David Beattie, Gillian M. Lamont, M. Raymond V. Finlay, Joanne Wilson, Aaron Smith, Lenka Oplustil O’Connor, Stephanie Ling, Stephen E. Fawell, Mark J. O’Connor, Simon J. Hollingsworth, Emma Dean, Frederick W. Goldberg, Barry R. Davies, Elaine B. Cadogan   +24 more
doaj   +1 more source

Remarks on the Standard Model predictions for $R(D)$ and $R(D^*)$

, 2016
Semileptonic $b \to c$ transitions, and in particular the ratios $R(D^{(*)}) = \frac{Γ(B \rightarrow D^{(*)} τν)}{Γ(B \rightarrow D^{(*)} \ell ν)}$, can be used to test the universality of the weak interactions. In light of the recent discrepancies between the experimental measurements of these observables by BaBar, Belle and LHCb and the Standard ...
Kim, C. S., Lopez-Castro, G., Tostado, S. L., Vicente, A.   +3 more
openaire   +2 more sources

Survival Outcomes and Complications Among Canadian Children With Retinoblastoma: A Population‐Based Report From CYP‐C

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Purpose Retinoblastoma (RB) is the most common pediatric ocular cancer, yet population‐based data on survival and risk factors remain limited. This study aimed to describe survival in a large national RB cohort and identify predictors of death and complications.
Samuel Sassine, Ofélie Trudeau‐Ferrin, Caroline Laverdière, Patrick Hamel, Rosanne Superstein, Bénédicte Koukoui, Carole Provost, Paul C. Nathan, Vijay Ramaswamy, Furqan Shaikh, Brenda Gallie, Ashwin Mallipatna, Stephanie Kletke, Helen Dimaras, Hallie Coltin   +14 more
wiley   +1 more source

Tight Frame with Hahn and Krawtchouk Polynomials of Several Variables [PDF]

, 2014
Finite tight frames for polynomial subspaces are constructed using monic Hahn polynomials and Krawtchouk polynomials of several variables. Based on these polynomial frames, two methods for constructing tight frames for the Euclidean spaces are designed ...
Xu, Yuan
core   +1 more source

Boosting neuraminidase immunity in the presence of hemagglutinin with the next generation of influenza vaccines

npj Vaccines
Neuraminidase (NA), the second most abundant surface glycoprotein on the influenza virus, plays a key role in viral replication and propagation. Despite growing evidence showing that NA-specific antibodies correlate with resistance to disease in humans ...
Guadalupe Cortés, Irina Ustyugova, Timothy Farrell, Clint McDaniel, Colleen Britain, Christopher Romano, Siré N’Diaye, Lingyi Zheng, Mithila Ferdous, Justin Iampietro, Svetlana Pougatcheva, Lauren La Rue, Liqun Han, Fuqin Ma, Svetlana Stegalkina, Satyajit Ray, Jianxin Zhang, Mario Barro   +17 more
doaj   +1 more source

Personalized Selumetinib Dosing in Pediatric Neurofibromatosis Type 1: Insights From a Pilot Therapeutic Drug Monitoring Study

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Objective To evaluate selumetinib exposure using therapeutic drug monitoring (TDM) in pediatric patients with neurofibromatosis type 1 (NF1) and plexiform neurofibromas (PN), assess interpatient pharmacokinetic variability, and explore the relationship between drug exposure, clinical response, and adverse effects.
Janka Kovács, Zoltán Köllő, Balázs Gellért Karvaly, Mahmoud Obeidat, Rita Nagy, Péter Hegyi, Brigitta Teutsch, Eszter Tuboly, Miklós Garami   +8 more
wiley   +1 more source

Motivating Employees in R&D [PDF]

, 2010
[Excerpt] A new medicine can take as long as 15 years to develop and may cost a pharmaceutical research company $1.3 billion or more from the laboratory to the pharmacy shelf.
McAllister, Ryan B., Vandlen, Chelsea E.
core   +1 more source

Developing R&D capacity in a primary care trust : use of the R&D culture index [PDF]

, 2006
There has traditionally been a low level of engagement of primary care practitioners with research. In the UK, primary care trusts (PCTs) now have some responsibility for the encouragement of research and development in primary care.
Clarke, Charlotte, Jelley, Diana, Walker, Caron, Watson, Bill, Whitford, David   +4 more
core   +1 more source

CRISPR GUARD protects off-target sites from Cas9 nuclease activity using short guide RNAs

Nature Communications, 2020
Off-target editing remains a concern for therapeutic applications of CRISPR-Cas9. Here the authors present CRISPR GUARD, which uses very short non-cleaving gRNAs to prevent editing at off-target sites.
Matthew A. Coelho, Etienne De Braekeleer, Mike Firth, Michal Bista, Sebastian Lukasiak, Maria Emanuela Cuomo, Benjamin J. M. Taylor   +6 more
doaj   +1 more source

Adherence to Protocol Recommendations for Children With Wilms Tumour in Two Consecutive Studies in the United Kingdom and Ireland—Does Variation Matter?

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Background and Aims Wilms tumour (WT) has excellent event‐free and overall survival (OS). However, small differences exist between countries participating in the same international study. This led us to examine variation in adherence to protocol recommendations as a potential contributing factor.
Suzanne Tugnait, R. Al‐Saadi, A. Lopez‐Cortes, K. Dzhuma, M. Oostveen, J. Brok, S. Irtan, M. Weeks, J. Bate, S. Baker, R. Williams, M. Powis, D. Saunders, O. Olsen, T. Watson, S. Shelmerdine, S. Vaidya, L. Howell, C. Duncan, G. M. Vujanic, C. Stiller, G. P. Balchin, T. Chowdhury, K. Pritchard‐Jones   +23 more
wiley   +1 more source